Clinical effect of goserelin combined with bicalutamide on patients after metastatic prostate cancer operation
Ma Min
Wu Haixiao
Wu Han
Sun Peng
Ye Jianan
Abstract：Objective To explore the clinical effect of goserelin combined with bicalutamide on patients after metastatic prostate cancer operation.Methods Totally 104 patients with metastatic prostate cancer from June 2014 to June 2015 in Jinhua Central Hospital in Zhejiang Province were randomly divided into control group and observation group,with 52 cases in each group.After bilateral orchiectomy,the control group had normal nursing and treatment;the observation group had bicalutamide 50 mg/time,1 time/d orally and goserelin 3.6 mg/time,once every 4 weeks subcutaneous injection.The serum level of prostate specific antigen (PSA) was tested before and 1,3,6,12 month after treatment.Clinical efficacy and incidence of adverse reaction were analyzed.Results The total effective rate in observation group was significantly higher than that in control group [90.4％ (47/52) vs 69.2％ (36/52)] (P ＜ 0.05).Serum levels of PSA after 1,3,6,12 months in observation group were significantly lower than those in control group[(8.6 ±3.6) μg/L vs (21.4 ±5.8) μg/L,(4.8 ± 1.7) μg/L vs (16.5 ±4.2)μg/L,(3.2 ± 1.1)μg/L vs (11.2 ±3.3)μg/L,(2.8 ±0.9)μg/L vs (9.0 ±2.7)μg/L] (P ＜0.05).Serum levels of PSA after treatment were significantly lower than those before treatment in both group [observation group:(96.9 ± 35.1) μg/L;coutrol group:(96.6 ± 34.6) μg/L] (P ＜ 0.05).The incidence of adverse reactions had no significant difference between groups (P ＞ 0.05).Conclusion Postoperative application of goserelin and bicalutamide can improve effect of orchiectomy on patients with metastatic prostate cancer and control serum level of PSA.
Keywords：Prostatic neoplasmsOrchiectomyGoserelinBicalutamide
Publication Date：2017-01-01
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：4( 403-406 )